All the in vitro and in vivo results demonstrate that LETX-VI promotes the synthesis and secretion of dopamine via multiple mechanisms including preventing abnormal accumulation of α-synuclein, increases the level of dopamine and shows implications in the prevention and treatment of PD via endogenous pathways. This evidence concerns the gene SNCA and Parkinson disease.